tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolytic-Uremic Syndrome D006463 2 associated lipids
Pancytopenia D010198 6 associated lipids
Nervous System Diseases D009422 37 associated lipids
Ataxia D001259 20 associated lipids
Psoriasis D011565 47 associated lipids
Urinary Tract Infections D014552 11 associated lipids
Brain Edema D001929 20 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Respiratory Insufficiency D012131 10 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Gingivitis D005891 3 associated lipids
Periodontal Pocket D010514 9 associated lipids
Brain Infarction D020520 17 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Stroke D020521 32 associated lipids
Liver Cirrhosis, Biliary D008105 12 associated lipids
Hyperbilirubinemia D006932 11 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Nephritis, Interstitial D009395 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Fredericks S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. 2006 Transplantation pmid:16969296
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Morrissey PE Prope tolerance: is it the end or the means? 2009 Transplantation pmid:19502973
Alloway RR Mounting Clinical Evidence With Tacrolimus Generic Products. 2017 Transplantation pmid:28749820
Prókai Á et al. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. 2016 Transplantation pmid:26502369
Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. 1994 Transplantation pmid:7513911
Lee D et al. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. 2017 Transplantation pmid:27779572
Yang CW et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. 2001 Transplantation pmid:11740384
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
McGhee B et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. 1997 Transplantation pmid:9326429
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Soccal PM et al. Improvement of drug-induced chronic renal failure in lung transplantation. 1999 Transplantation pmid:10428288
Muthukumar T et al. HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles. 2013 Transplantation pmid:23503504
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Gallon L et al. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. 2015 Transplantation pmid:25905982
Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2007 Transplantation pmid:17297401
Murase N et al. FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. 1990 Transplantation pmid:1700504
Burke MD et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. 1990 Transplantation pmid:1700507
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Abu-Qaoud MS et al. Lack of relationship between microvascular and macrovascular disease in heart transplant recipients. 2012 Transplantation pmid:23044666
Woodward RS et al. Renal graft survival and calcineurin inhibitor. 2005 Transplantation pmid:16177637
Barten MJ et al. Synergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. 2004 Transplantation pmid:15114077
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Uemura T et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. 2011 Transplantation pmid:21841541
Aw MM et al. Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. 2001 Transplantation pmid:11544444
Terakura M et al. Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. 1998 Transplantation pmid:9721804
Kai N et al. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. 1993 Transplantation pmid:7682740
Jacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. 2011 Transplantation pmid:21206424
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Vafadari R et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. 2012 Transplantation pmid:22960764
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
Lerut J et al. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. 2005 Transplantation pmid:16314784
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920
Meiser BM et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? 2004 Transplantation pmid:15446320
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Jordan ML et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. 1994 Transplantation pmid:7512293
Sun S et al. Effect of tacrolimus on hemodynamics and absorption of experimental small intestinal transplants. 1996 Transplantation pmid:8633368
Kashu Y et al. The effect of combination splenectomy and low-dose FK506 therapy on graft survival after liver allograft transplantation in rats. 1996 Transplantation pmid:8633382